Denali Advisors LLC Has $689,000 Stake in AstraZeneca PLC $AZN

Denali Advisors LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 35.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,975 shares of the company’s stock after selling 5,002 shares during the quarter. Denali Advisors LLC’s holdings in AstraZeneca were worth $689,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Cibc World Market Inc. lifted its holdings in AstraZeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after purchasing an additional 11,398 shares in the last quarter. Y Intercept Hong Kong Ltd raised its position in shares of AstraZeneca by 111.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after buying an additional 35,148 shares during the last quarter. Oxbow Advisors LLC lifted its holdings in shares of AstraZeneca by 96.2% in the third quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after buying an additional 38,043 shares in the last quarter. Assetmark Inc. boosted its position in shares of AstraZeneca by 6.5% during the third quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock worth $23,813,000 after acquiring an additional 19,020 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in AstraZeneca by 10.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 191,518 shares of the company’s stock valued at $16,156,000 after acquiring an additional 17,548 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Price Performance

AstraZeneca stock opened at $205.47 on Tuesday. AstraZeneca PLC has a 12-month low of $122.48 and a 12-month high of $206.71. The firm has a 50-day moving average price of $115.01 and a 200-day moving average price of $93.99. The firm has a market capitalization of $318.66 billion, a PE ratio of 68.26, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca Announces Dividend

The business also recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. This represents a dividend yield of 165.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is currently 74.83%.

Wall Street Analysts Forecast Growth

Several analysts have commented on AZN shares. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Citigroup initiated coverage on AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. Barclays restated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.